Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905080 | 0.84 | HPRT1 (0.41) | TYMPENPP1POLBHSD17B10HPRT1 | |
| SCHEMBL14237174 | 0.78 | POLB (0.45) | POLBHSD17B10DUTALDH1A1LMNA | |
| SCHEMBL6319799 | 0.76 | FGFR1 (0.52) | TYMPHPRT1FGFR1SLC22A6LMNA | |
| SCHEMBL16038119 | 0.74 | TYMP (0.58) | TYMPENPP1DUTFGFR1SLC22A6 | |
| SCHEMBL6902587 | 0.71 | FGFR1 (0.47) | ENPP1HPRT1FGFR1SLC22A6 | |
| SCHEMBL16038187 | 0.70 | PKM (0.43) | TYMPENPP1POLBHSD17B10DUT | |
| SCHEMBL6901448 | 0.68 | HPRT1 (0.76) | POLBHSD17B10HPRT1 | |
| SCHEMBL25701039 | 0.68 | POLB (0.40) | TYMPENPP1POLBHSD17B10DUT | |
| SCHEMBL23171170 | 0.67 | POLB (0.44) | POLBHSD17B10DUTALDH1A1LMNA | |
| SCHEMBL6055280 | 0.67 | POLB (0.43) | POLBHSD17B10DUTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | TYMP 1083/4885ENPP1 1794/4885POLB 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.